ArticleThoracic cancer2026
Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2-CAR-T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is highly relapsed and responds poorly to chimeric antigen receptor (CAR)-T therapy due to antigenic heterogeneity and the immunosuppressive microenvironment. Trophoblast cell-surface antigen 2 (TROP2), overexpressed in LUAD and linked to poor prognosis, is a promising target. Radiofrequency ablation (RFA) can cause direct tumor necrosis, trigger immunogenic cell death, and enhance immune infiltration through antigen secretion; however, it often fails to eradicate residual tumors. Therefore, combining RFA with CAR-T-cell therapy may offer a new and synergistic therapy against LUAD.
objectiveThis study examined the cytotoxicity of TROP2-directed CAR-T cells against LUAD in vitro and observed their therapeutic efficacy and safety in combination with RFA in vivo.
methodsThird-generation TROP2-CAR-T cells were developed and characterized for transduction efficiency, CD4/CD8 ratio, and proliferative capacity. Their antigen-specific cytotoxicity against TROP2
resultsTROP2-CAR-T cells showed efficient transduction and potent, antigen-dependent cytotoxicity with significant cytokine secretion in vitro. In vivo, both RFA and TROP2-CAR-T therapy suppressed tumor growth, and their combination showed a synergistic antitumor effect without hepatic or renal toxicity.
conclusionThe combination of RFA and TROP2-CAR-T therapy demonstrates enhanced antitumor efficacy and improved safety profile in LUAD, highlighting a promising combinatorial immunotherapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.